Efficacy of infliximab biosimilars in patients with Crohn's disease

Davide Giuseppe Ribaldone¹, Giorgio Maria Saracco², Marco Astegiano³, Rinaldo Pellicano³

Affiliations

¹ Department of Medical Sciences, Division of Gastroenterology, University of Turin, 10126 Turin, Italy. Electronic address: davrib_1998@yahoo.com.
² Department of Medical Sciences, Division of Gastroenterology, University of Turin, 10126 Turin, Italy.
³ Department of Gastroenterology and Hepatology, City of Health and Science, Molinette Hospital, Turin, Italy.

PMID: 29208303
DOI: 10.1016/S0140-6736(17)33047-7

Free article

Comment

Efficacy of infliximab biosimilars in patients with Crohn's disease

Davide Giuseppe Ribaldone et al. Lancet. 2017.

Free article

. 2017 Dec 2;390(10111):2435-2436.

doi: 10.1016/S0140-6736(17)33047-7. Epub 2017 Dec 1.

Authors

Davide Giuseppe Ribaldone¹, Giorgio Maria Saracco², Marco Astegiano³, Rinaldo Pellicano³

Affiliations

¹ Department of Medical Sciences, Division of Gastroenterology, University of Turin, 10126 Turin, Italy. Electronic address: davrib_1998@yahoo.com.
² Department of Medical Sciences, Division of Gastroenterology, University of Turin, 10126 Turin, Italy.
³ Department of Gastroenterology and Hepatology, City of Health and Science, Molinette Hospital, Turin, Italy.

PMID: 29208303
DOI: 10.1016/S0140-6736(17)33047-7

No abstract available

PubMed Disclaimer

Comment in

Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply.
Jørgensen KK, Lundin KE, Olsen IC, Kvien TK, Jahnsen J. Jørgensen KK, et al. Lancet. 2017 Dec 2;390(10111):2436. doi: 10.1016/S0140-6736(17)32463-7. Epub 2017 Dec 1. Lancet. 2017. PMID: 29208304 No abstract available.

Comment on

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy of infliximab biosimilars in patients with Crohn's disease

Affiliations

Efficacy of infliximab biosimilars in patients with Crohn's disease

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical